Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections.

26 Mar 2014

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology.

26 Mar 2014

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis

N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).

12 Mar 2014

Genetic basis of hereditary disease causes severe brain atrophy in Jews of Moroccan ancestry

Ben-Gurion University of the Negev (BGU) researchers have unraveled the genetic basis of a hereditary disease that causes severe brain atrophy, mental retardation and epilepsy in Jews of Moroccan ancestry, according to a study published this week online in the Journal of Medical Genetics.

11 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Cystic fibrosis is a rare, life-shortening genetic disease for which there is no cure. It affects more than 75,000 people worldwide. In CF, thick, sticky mucus blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs airways in the lungs making it easier for bacteria to grow.

5 Mar 2014

Computational Fluid Dynamics helps patients with pulmonary disorders breathe easier

A more accurate and successful, yet complex approach used in designing an airplane is now taking off in the health care industry.

5 Mar 2014

Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

Brisbane's water supply has been found to contain disease carrying bugs which can be directly linked to infections in some patients, according to a new study by QUT.

3 Mar 2014

Heat shock protein may be involved in folding processes of tau protein

Proteins like the so-called heat shock protein Hsp90 play an important role in almost all processes within human cells. They help other proteins fold into their three-dimensional structure or return damaged proteins back into their proper shape.

3 Mar 2014

Link found between pollutants and certain metabolic complications of obesity

A team of researchers at the IRCM in Montr-al led by R-mi Rabasa-Lhoret, in collaboration with J-r-me Ruzzin from the University of Bergen in Norway, found a link between a type of pollutants and certain metabolic complications of obesity. Their breakthrough, published online this week by the Journal of Clinical Endocrinology & Metabolism, could eventually help improve the prevention, diagnosis, and treatment of cardiometabolic risk associated with obesity, such as diabetes, hypertension and cardiovascular disease.

28 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Researcher identifies ''conductor'' in development of muscle tissue

A team led by Jean-Fran-ois C-t-, researcher at the IRCM, identified a ''conductor'' in the development of muscle tissue. The discovery, published online yesterday by the scientific journal Proceedings of the National Academy of Sciences (PNAS), could have an important impact on the treatment of muscular diseases such as myopathies and muscular dystrophies.

26 Feb 2014

Scientists identify lung-damaging molecule in cystic fibrosis patients during symptom flare-ups

A molecule previously linked to lung injuries in factory workers producing microwave popcorn might play an important role in microbial infections of the lung suffered by people with cystic fibrosis (CF), according to a recent study led by San Diego State postdoctoral researcher Katrine Whiteson.

25 Feb 2014

Ajoene in garlic prevents bacteria from destroying white blood cells

Aggressive multi-resistant infections constitute an increasing health problem all over the world. Bacteria are developing resistance at an alarming pace, so new pharmaceuticals that can combat this threat are in great demand.

19 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

Nearly half of HIV-infected teenagers, young adults forego treatment

Nearly half of HIV-infected teenagers and young adults forego timely treatment, delaying care until their disease has advanced, which puts them at risk for dangerous infections and long-term complications, according to a study led by the Johns Hopkins Children's Center.

4 Feb 2014

Not all children, young adults treated achieve long-term relief from symptoms of anxiety

Fewer than one in two children and young adults treated for anxiety achieve long-term relief from symptoms, according to the findings of a study by investigators from the Johns Hopkins Children's Center and five other institutions.

30 Jan 2014

Cystic Fibrosis Center receives Quality Care Award for commitment to improve quality of care in CF patients

The Cystic Fibrosis Center at Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital has been selected by the Cystic Fibrosis Foundation (CFF) for the foundation's prestigious Quality Care Award for 2012-2013.

30 Jan 2014

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, announced that reported diluted earnings per share equaled $0.07 in the third quarter of fiscal 2014, compared to a reported loss per share of ($0.58) in the third quarter of fiscal 2013. The third quarter of fiscal 2014 included a $45 million charge ($28.2 million net of tax) related to Project Rejuvenate.

21 Jan 2014

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Aradigm reports record revenue of $4.6M in fourth quarter 2013

N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis

Genetic basis of hereditary disease causes severe brain atrophy in Jews of Moroccan ancestry

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Computational Fluid Dynamics helps patients with pulmonary disorders breathe easier

Scientists find certain species of nontuberculous mycobacteria in water that cause infection in humans

Heat shock protein may be involved in folding processes of tau protein

Link found between pollutants and certain metabolic complications of obesity

FDA approves KALYDECO for people with cystic fibrosis

Researcher identifies ''conductor'' in development of muscle tissue

Scientists identify lung-damaging molecule in cystic fibrosis patients during symptom flare-ups

Ajoene in garlic prevents bacteria from destroying white blood cells

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Nearly half of HIV-infected teenagers, young adults forego treatment

Not all children, young adults treated achieve long-term relief from symptoms of anxiety

Cystic Fibrosis Center receives Quality Care Award for commitment to improve quality of care in CF patients

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in